Aridis Pharmaceuticals Inc. Common Stock
ARDS
ARDS was delisted on the 18th of July, 2023.
6 hedge funds and large institutions have $550K invested in Aridis Pharmaceuticals Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 1 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
34% more capital invested
Capital invested by funds: $411K → $550K (+$139K)
0.03% more ownership
Funds ownership: 1.04% → 1.07% (+0.03%)
0% more funds holding
Funds holding: 6 → 6 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$19.1K |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
+$6.59K |
| 3 |
BlackRock
New York
|
+$3.63K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$242 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$6.65K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$3K |
ARDS Hedge Fund Activity: Q1 2020 in Review
6 of the 4,548 institutional investors tracked by Wall St. Rank reported a position in Aridis Pharmaceuticals Inc. Common Stock (ARDS) for Q1 2020, worth a combined $550K — up 34% from $411K a quarter earlier.
Fund positioning in ARDS was balanced in Q1 2020: 1 fund opened new positions, 1 closed out, 3 added to existing stakes and 1 trimmed.
The largest buyer was Bank of America, adding an estimated $19.1K. The largest seller was Millennium Management, cutting an estimated $6.65K.
- 6 institutional investors held Aridis Pharmaceuticals Inc. Common Stock (ARDS) as of Q1 2020, unchanged from Q4 2019.
- Funds reported $550K of Aridis Pharmaceuticals Inc. Common Stock stock for Q1 2020, up 34% quarter-over-quarter.
- 1 fund opened new Aridis Pharmaceuticals Inc. Common Stock positions in Q1 2020 and 1 closed out, a net change of 0 holders.
- The largest Aridis Pharmaceuticals Inc. Common Stock buyer in Q1 2020 was Bank of America, an estimated $19.1K added.
- The largest Aridis Pharmaceuticals Inc. Common Stock seller in Q1 2020 was Millennium Management, an estimated $6.65K sold.
Based on aggregated 13F filings for Q1 2020.